NovoCure Limited - Ordinary Shares (NVCR) News
Filter NVCR News Items
NVCR News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest NVCR News From Around the Web
Below are the latest news stories about NovoCure Ltd that investors may wish to consider to help them evaluate NVCR as an investment opportunity.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open.
Has NovoCure Limited (NASDAQ:NVCR) Stock's Recent Performance Got Anything to Do With Its Financial Health?
NovoCure's (NASDAQ:NVCR) stock up by 5.6% over the past three months. As most would know, long-term fundamentals have...
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
Novocure (NVCR) has launched MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home.Novocure initiated a phased launch with an initial wave of 30 U.S. patients to be followed by a broad rollout to all patients in the coming months. Optune is...
Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data
ST. HELIER, Jersey--(BUSINESS WIRE)--A new tool will enable patients to download their Optune usage data without the need for an in-person visit by a Novocure Device Support Specialist.
Novocure and Zai Lab announced that China NMPA approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma.
Q1 2020 Novocure Ltd Earnings Call
NovoCure Limited (NASDAQ:NVCR), which is in the medical equipment business, and is based in Jersey, received a lot of...
On behalf of the entire NovoCure team, we would like to begin by wishing you well as we collectively face the challenges of the COVID-19 pandemic. Pritesh Shah, our Chief Commercial Officer; and Ely Benaim, our Chief Medical Officer, are also on the call and available for Q&A.
NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?